

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-45. (cancelled)

46. (previously added) A method for imaging of lymphatic vasculature in tissue, comprising the step of contacting the tissue with an antibody which interferes with binding of VEGF-D to a VEGF receptor-3, and detecting the occurrence of binding of said antibody.

47. (previously added) A method according to Claim 46, wherein said antibody is a monoclonal antibody selected from the group consisting of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652), and 5F12 (ATCC No. PTA-3651), or a F(ab')<sub>2</sub>, F(ab'), F(ab) fragment or chimeric antibody thereof.

48. (previously added) A method according to Claim 46, wherein the antibody is labeled covalently or noncovalently with a detectable label.

49. (previously added) A method according to Claim 49, wherein the detectable label is selected from the group consisting of supermagnetic agent, a paramagnetic agent, an electron dense agent, an ecogenic agent, and a radioactive agent.

50. (previously added) A method according to Claim 49, wherein the detectable label is selected from the group consisting of <sup>125</sup>I, <sup>32</sup>P, an enzymatic label, and a fluorimetric labels.

51. (previously added) A method according to Claim 50, wherein the enzymetic label is horseradish peroxidase.

52. (previously added) A method according to Claim 50, wherein the fluorimetric label is fluorescein-5-isothiocyanate (FITC).

53. (new). An antibody that specifically binds to a polypeptide having the amino acid sequence as set forth in SEQ ID NO:1.

54. (new) The antibody according to Claim 53, wherein said antibody is a monoclonal antibody, or a F(ab')<sub>2</sub>, F(ab'), F(ab) fragment or a chimeric antibody or a humanized antibody thereof.

55. (new) The antibody according to claim 53, wherein said antibody is labeled with a detectable label.

56. (new) The antibody according to claim 55, wherein said detectable label is a radioactive isotope.

57. (new) The antibody according to claim 53, wherein said antibody is a human antibody.

58. (new) An antibody which interferes with the activity of VEGF-D mediated by a VEGF receptor-2, wherein said antibody binds specifically to a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1.

59. (new) The antibody of Claim 58, which is a monoclonal antibody or a F(ab')<sub>2</sub>, F(ab'), F(ab) fragment or a chimeric antibody or a humanized antibody thereof.

60. (new) The antibody of Claim 58, wherein said antibody does not interfere with the activity of VEGF mediated by a VEGF receptor-2.

61. (new) The antibody according to claim 58, wherein said antibody does not bind to VEGF-C.

62. (new) The antibody according to claim 58, wherein said antibody interferes with the binding of VEGF-D to a VEGF receptor-3.

63. (new) A composition, comprising an antibody according to claim 58, and a pharmaceutically acceptable carrier.

64. (new) An antibody which interferes with the activity of VEGF-D mediated by a VEGF receptor-3, wherein said antibody binds specifically to a polypeptide having an amino acid sequence set forth in SEQ ID NO: 1.